RP-6306 ((S)-RP-6306) is a potent, selective and orally active PKMYT1 inhibitor with an IC 50 of 14 nM. RP-6306 shows a high degree of selectivity over other kinases in cellular binding assays. RP-6306 shows anticancer effects.
性状
Solid
IC50 & Target[1][2]
IC50: 14 nM (PKMYT1)
体外研究(In Vitro)
RP-6306(500nM;持续 24h)处理在 HCC1569 乳腺癌细胞系中诱导 pan-γH2AX,表明肿瘤衍生的 CCNE1 扩增也使细胞在 PKMYT1 抑制后容易受到 DNA 损伤诱导。RP-6306 处理会在 CCNE1 过表达细胞中选择性地意外激活 CDK1,从而促进正在进行 DNA 合成的细胞的早期有丝分裂。 has not independently confirmed the accuracy of these methods. They are for reference only.
体内研究(In Vivo)
在 CCNE1 扩增的卵巢异种移植模型 (OVCAR3) 中,RP-6306 (15, 50, and 300 ppm; oral; daily; for 21 days) 导致 OVCAR3 肿瘤生长显着减少且呈剂量依赖性 。 has not independently confirmed the accuracy of these methods. They are for reference only.
Animal Model: OVCAR3-bearing mice
运输条件
Room temperature in continental US; may vary elsewhere.
储存方式
Powder -20°C 3 years;4°C 2 years
ClinicalTrial
参考文献
[1]. Janek Szychowski, et al. Discovery of an Orally Bioavailable and Selective PKMYT1 Inhibitor, RP-6306. J Med Chem. 2022 Aug 11;65(15):10251-10284. [2]. David Gallo, et al. CCNE1 amplification is synthetic lethal with PKMYT1 kinase inhibition. Nature. 2022 Apr;604(7907):749-756.
溶解度数据
In Vitro: DMSO : 50 mg/mL (154.14 mM; Need ultrasonic)配制储备液